166108-71-0

Basic information

• Product Name: [2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic acid
• Synonyms: Fmoc-8-amino-3,6-dioxaoctanoic acid, Fmoc-AEEA;1-(9H-Fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azadodecan-12-oic acid;Fmoc-PEG2- CH2COOH (Fmoc-AEEA);Fmoc-PEG2-acetic acid;{2-[2-(Fmoc-amino)ethoxy]ethoxy}acetic acid≥ 99% (HPLC);Fmoc-NH-(PEG)-COOH (9 atoms) Novabiochem;1-(9H-Fluoren-9-yl)-3-oxo-2,7,1-trioxa-4-azadodecan-12-oic acid;9-FLUORENYLMETHOXYCARBONYL-8-AMINO-3,6-DIOXAOCTANOIC ACID
• CAS NO: 166108-71-0
• Molecular Formula: C₂₁H₂₃NO₆
• Molecular Weight: 385.41
• Mol File: 166108-71-0.mol
• Article Data: 4

Chemical Properties

• Melting Point: 90-92℃
• Boiling Point: 631.4 °C at 760 mmHg
• Flash Point: 335.6 °C
• Appearance: White/Crystalline Powder
• Density: 1.265 g/cm³
• Vapor Pressure: 8.27E-17mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: -15°C
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 3.40±0.10(Predicted)
• CAS DataBase Reference: [2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic acid(166108-71-0)
• EPA Substance Registry System: [2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic acid(166108-71-0)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 166108-71-0(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 166108-71-0 differently. You can refer to the following data:
1. [2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic acid is a hydrophilic, heterobifunctional spacer.
2. Hydrophillic spacer group.
3. 8-(Fmoc-amino)-3,6-dioxaoctanoic Acid is a hydrophilic, heterobifunctional spacer.

Description

Fmoc-NH-PEG2-CH2COOH is a PEG linker containing an Fmoc-protected amine and a terminal carboxylic acid. The hydrophilic PEG spacer increases solubility in aqueous media. The Fmoc group can be deprotected under basic condition to obtain the free amine which can be used for further conjugations. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond.

Chemical Properties

White solid

InChI:InChI=1/C21H23NO6/c23-20(24)14-27-12-11-26-10-9-22-21(25)28-13-19-17-7-3-1-5-15(17)16-6-2-4-8-18(16)19/h1-8,19H,9-14H2,(H,22,25)(H,23,24)

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 134978-97-5 [2-(N-2-amino ethoxy)ethoxy] acetic acid 
• 75001-09-1 2-(2-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)ethoxy)acetic acid 
• 1122484-77-8 [2-(2-aminoethoxy)ethoxy]acetic acid tert-butyl ester 
• 75001-08-0 2-{2-[2-(2-hydroxyethoxy)ethoxy]ethyl}isoindole-1,3-dione 
• 5197-62-6 2-[2-(chloroethoxy)ethoxy]ethanol 
• 6338-55-2 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol 
• 560088-66-6 [2-[2-(2-hydroxyethoxy)ethoxy]ethyl]carbamic acid 9H-fluoren-9-ylmethyl ester 
• 166108-70-9 [2-(2-dibenzylaminoethoxy)ethoxy]acetic acid 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 

Downstream Products

• 926646-70-0 2'-(4-hydroxy-phenyl)-6-(4-methyl-piperazin-1-yl)-1H,3'H-[2,5']bibenzoimidazolyl-4-carboxylic acid (2-{2-[(2-{2-[(2-{2-[(2-mercapto-ethylcarbamoyl)-methoxy]-ethoxy}-ethylcarbamoyl)-methoxy]-ethoxy}-ethylcarbamoyl)-methoxy]-ethoxy}-ethyl)-amide 
• 1012050-22-4 C₄₉H₆₂N₁₂O₁₁ 
• 1206723-87-6 C₃₉H₄₂N₂O₈ 
• 919529-68-3 C₄₅H₅₃N₅O₉ 
• 1321923-36-7 FmocNH-DEG-CH₂CONH-Gly-Phe-Leu-Gly-OBn 
• 1321923-37-8 FmocNH-DEG-CH₂CONH-Gly-Phe-Leu-Gly-OH 
• 1321923-38-9 FmocNH-DEG-CH₂CONH-Gly-Phe-Leu-Gly-EDADNS 
• 1321923-28-7 H₂N-DEG-CH₂CONH-Gly-Phe-Leu-Gly-EDADNS 
• 1420656-56-9 C₁₅₉H₂₃₉N₂₅O₃₅S₂ 

Relevant articles and documents

Novel linker compound and Site-Specific compounds of Antibody-Drug Conjugate Comprising the Same

The present invention relates to a novel linker compound, and relates to a site-specific antibody-drug conjugate (ADC) compound comprising the same, a method for manufacturing the same, and an anticancer composition comprising the same as an active component. The linker compound produces a uniform ADC compound with excellent site specificity in manufacturing an ADC compound, and the ADC compound comprising the same exhibits an excellent anticancer effect.COPYRIGHT KIPO 2020

A convenient route to diversely substituted icosahedral closomer nanoscaffolds

The design and synthesis of icosahedral polyhedral borane closomer motifs based upon carbonate and carbamate anchoring groups for biomedical applications are described. Dodecacarbamate closomers containing easily accessible groups of interest at their linker termini were synthesized via activation of the B-OH vertices as aryl carbonates and their subsequent reaction with primary amines. Novel dodecacarbonate closomers were successfully synthesized for the first time by reacting [closo-B12(OH)12]2- with an excess of respective aryl chloroformates, utilizing relatively short reaction times, mild conditions and simple purification strategies, all of which had previously presented difficulties in closomer chemistry. This methodology for the 12-fold degenerate synthesis of carbonate and carbamate closomers will greatly facilitate further exploration of closomers as monodisperse nanomolecular delivery platforms.